Targeted Delivery of Radioisotopes to Solid Tumours Using Bicyclic Radionuclide Conjugates Directed at Novel Tumor-Associated Antigens
- Explaining how screening platforms can identify novel peptide binders to challenging targets and optimise them into highaffinity, selective molecules
- Highlighting the creation of targeted radionuclide conjugates aimed at MT1-MMP and EphA2 for precision therapy
- Presenting preclinical findings on proteins widely expressed across cancers with significant unmet clinical needs